<DOC>
<DOCNO>EP-0934290</DOCNO> 
<TEXT>
<INVENTION-TITLE>
AMINOTHIAZOLE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P2518	A61K3100	A61P2500	A61K31427	C07D41712	A61K31425	A61K31427	C07D27740	C07D27742	C07D27700	A61P3706	A61P4300	A61P3700	A61P538	A61K31426	C07D27720	A61P2522	A61P100	A61K4500	A61P100	A61P2900	A61K31425	A61P500	A61P3700	A61K3100	A61P2524	A61K4500	A61K31426	C07D41700	A61P2900	A61P4300	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61K	A61P	A61K	C07D	A61K	A61K	C07D	C07D	C07D	A61P	A61P	A61P	A61P	A61K	C07D	A61P	A61P	A61K	A61P	A61P	A61K	A61P	A61P	A61K	A61P	A61K	A61K	C07D	A61P	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P25	A61K31	A61P25	A61K31	C07D417	A61K31	A61K31	C07D277	C07D277	C07D277	A61P37	A61P43	A61P37	A61P5	A61K31	C07D277	A61P25	A61P1	A61K45	A61P1	A61P29	A61K31	A61P5	A61P37	A61K31	A61P25	A61K45	A61K31	C07D417	A61P29	A61P43	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention concerns compounds of formula (I) in which R1, R2, R3, R4, R5 and R6 are such as defined in claim 1. The compounds have a strong affinity for CRF receptors.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SANOFI SYNTHELABO
</APPLICANT-NAME>
<APPLICANT-NAME>
SANOFI-SYNTHELABO
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
FONTAINE EVELYNE
</INVENTOR-NAME>
<INVENTOR-NAME>
GULLY DANIELLE
</INVENTOR-NAME>
<INVENTOR-NAME>
ROGER PIERRE
</INVENTOR-NAME>
<INVENTOR-NAME>
WERMUTH CAMILLE GEORGES
</INVENTOR-NAME>
<INVENTOR-NAME>
FONTAINE, EVELYNE
</INVENTOR-NAME>
<INVENTOR-NAME>
GULLY, DANIELLE
</INVENTOR-NAME>
<INVENTOR-NAME>
ROGER, PIERRE
</INVENTOR-NAME>
<INVENTOR-NAME>
WERMUTH, CAMILLE, GEORGES
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Compound of formula:


wherein:

R
1
 and R
2
 which may be identical or different each
represent, independently of one another, a halogen atom;

a (C
1-5
)hydroxyalkyl; a (C
1-5
)alkyl; an aralkyl wherein the
aryl moiety is (C
6-8
) and the alkyl part is (C
1-4
) ; a
(C
1-5
)alkoxy; a trifluoromethyl group; a nitro group; a
nitrile group; a group -SR wherein R denotes hydrogen, a

(C
1-5
)alkyl or an aralkyl wherein the aryl part is
(C
5-8
)and the alkyl part is (C
1-4
); a group -S-CO-R
o

wherein R
o
 denotes a (C
1-5
)alkyl radical or an aralkyl
wherein the aryl part is (C
5-8
)and the alkyl part is
(C
1-4
); a group -COORa wherein Ra denotes hydrogen or a
(C
1-5
)alkyl; a group -CONRaRb wherein Ra and Rb are as
hereinbefore defined for Ra; a group -NRaRb wherein Ra

and Rb are as hereinbefore defined for Ra; a group
-CONRcRd or -NRcRd wherein Rc and Rd together with the

nitrogen atom to which they are linked form a 5- to 7-membered
heterocyclic group; or a group -NHCO-NRaRb

wherein Ra and Rb are as hereinbefore defined for Ra;
R
3
 denotes hydrogen or is as defined for R
1
 and R
2

hereinbefore;
R
4
 denotes a (C
1-5
)alkyl; a hydroxymethyl group; a
formyl group; or a halogen atom;
R
5
 denotes a (C
1-5
)alkyl; a cycloalkylalkyl group 
wherein the cycloalkyl group is (C
3-7
) and the alkyl is
(C
1-5
); an alkenyl group having 3 to 6 carbon atoms; a
(C
1-5
)hydroxyalkyl group; an alkylcarbonyloxyalkyl group
wherein the alkyls are (C
1-5
); or an alkynyl group having
3 to 6 carbon atoms;
R
6
 denotes a phenyl substituted by one or more
substituents Z as defined hereinafter; a monocyclic 5-7-membered

heteroaromatic group substituted by one or more
radicals Z as defined hereinafter; or a 9- or 10-membered

bicyclic group consisting of an aromatic
monocyclic group optionally having one or more

heteroatoms selected from among O, N and S, fused to a
cycloalkyl group optionally comprising in the ring one

or more heteroatoms selected from among O, N and S, said
bicyclic group being substituted by one or more

substituents Z as defined hereinafter and which is
connected to the nitrogen by the aromatic ring, given

that R
6
 does not denote a substituted indane and the
substituent Z denotes a radical selected from among: a

halogen atom, a nitro group, a hydroxy group, a
trifluoromethyl group, a (C
1-5
)alkyl, a (C
1-5
) thioalkyl, a
group -NRaRb wherein Ra and Rb are as hereinbefore

defined for Ra, a (C
1-5
)hydroxyalkyl, a (C
1-5
)alkoxy, a
trifluoromethyloxy group, an alkoxyalkyl wherein the

alkyls are (C
1-5
), a group -COORa wherein Ra is as
hereinbefore defined, a group -CONRaRb wherein Ra and Rb

are as hereinbefore defined for Ra, a
carboxyl(C
1-5
)alkyl, an alkoxycarbonylalkyl wherein the
alkyls are (C
1-5
), a (C
1-5
)alkylcarbonyl, an
alkylcarbonylalkyl wherein the alkyls are (C
1-5
), a
morpholinocarbonyl or morpholinocarbonyl (C
1-5
) alkyl
group, or a group -NRaCOORb wherein Ra and Rb are as

hereinbefore defined, a group -NHCOR
e
 wherein R
e
 denotes
a (C
1-8
)alkyl, a cycloalkylcarbonyl wherein the
cycloalkyl is (C
3-6
), a cycloalkylalkylcarbonyl wherein
the cycloalkyl is (C
3-6
) and the alkyl is (C
1-3
), a 
benzoyl, a phenyl which is unsubstituted or substituted

by a (C
1-5
)alkyl, by a (C
1-5
)alkoxy, by a halogen atom, by
a nitro group, by a hydroxy group or by a

trifluoromethyl group;

the stereoisomers, the addition salts, the hydrates
and/or the solvates thereof.
Compound of formula (I) according to claim 1,
wherein R
6
 denotes a phenyl or tetrahydronaphthyl group
substituted by one or more substituents Z as defined for

(I), R
1
, R
2
, R
3
, R
4
 and R
5
 also being as defined for (I),
one of the stereoisomers, one of the salts, one of the

hydrates and/or one of the solvates thereof.
Compound of formula (I) according to claims 1 and
2, wherein R
4
 denotes a methyl, R
1
, R
2
, R
3
, R
4
 and R
5
 being
as defined for (I), one of the stereoisomers, one of the

hydrates and/or one of the solvates thereof.
Compound of formula (I) according to claim 3,
wherein R
1
 and/or R
2
 denotes a halogen, a
trifluoromethyl, a (C
1-5
)alkyl or a (C
1-5
)alkoxy, R
4

denotes a methyl, R
6
 denotes a phenyl at least
substituted in the 2 position by a substituent Z as

defined for (I), R
3
 and R
5
 are as defined for (I), one of
the stereoisomers, one of the salts, one of the hydrates

and/or one of the solvates thereof.
Compound according to claim 1 selected from among:

4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(5-ethoxycarbonyl-2-methoxyphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(5-chloro-2-methylphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-trifluoromethylphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-methoxyphenyl)-N-propylamino]thiazole 
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2,6-dichlorophenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2,5-dichlorophenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-chloro-5-methylphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-chloro-5-trifluoromethylphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-chloro-5-methoxyphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(5-chloro-2-methoxyphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(5-chloro-2-ethoxyphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-methoxy-5-methylphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2,5-dimethylphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2,5-ditrifluoromethylphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-methoxy-5-trifluoromethylphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2,5-dimethoxyphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-methoxy-5-methoxycarbonylphenyl)-N-propylamino]thiazole
4-(2,4-dichlorophenyl)-5-methyl-2-[N-(2,5-dichlorophenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(5-acetyl-2-methoxyphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-(methoxy)-5-(phenyl)phenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2,6-dimethoxyphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-methoxy-6-methylphenyl)-N-propylamino]thiazole 
4-(2,4-dichlorophenyl)-5-methyl-2-[N-(2-methoxy-6-methylphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(5-ethyl-2-methoxyphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(5-bromo-2-methoxyphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-methoxy-5-o-tolylphenyl)-N-propylamino]thiazole
4-(2,4,6-trichlorophenyl)-5-methyl-2-[N-(2,5-ditrifluoromethylphenyl)-N-propylamino]thiazole
4-(2,4-dichlorophenyl)-5-methyl-2-[N-(2,5-ditrifluoromethylphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-methoxy-5-nitrophenyl)-N-propylamino]thiazole
4-(2,4-dichlorophenyl)-5-methyl-2-[N-(2,6-dichloro-5-methylphenyl)-N-propylamino]thiazole
4-(2,4-dichlorophenyl)-5-methyl-2-[N-(2-methoxy-6-methylphenyl)-N-propylamino]thiazole
4-(2,4-dichlorophenyl)-5-methyl-2-[N-(5-chloro-2-methylphenyl)-N-propylamino]thiazole
4-(4-chloro-2-trifluoromethylphenyl)-5-methyl-2-[N-(5-chloro-2-methylphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxy-5-methylphenyl)-5-methyl-2-[N-(2-methoxy-5-methylphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-methylthio-5-trifluoromethylphenyl)-N-propylamino]thiazole
4-(2,4-dichloro-5-methylphenyl)-5-methyl-2-[N-(2-methoxy-5-methylphenyl)-N-propylamino]thiazole
4-(2-dichloro-4,5-dimethylphenyl)-5-methyl-2-[N-(2-methoxy-5-methylphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-methoxy-5-methoxycarbonylphenyl)-N-propylamino]thiazole
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(5-chloro-2-methylphenyl)-N-prop-2-ynylamino]thiazole,
 
one of the stereoisomers, one of the salts, one of the

hydrates and/or one of the solvates thereof.
Process for preparing the compounds of formula (I)
according to claim 1, 
characterised in that
 an alpha-halogenated
derivative of formula (III)



wherein R
1
, R
2
, R
3
 and R
4
 are as defined for (I) and Hal
denotes a halogen atom, preferably bromine or chlorine,

is reacted either with a thiourea (METHOD A) of formula:


wherein R
6
 is as defined for (I) to obtain a compound of
formula (II)



wherein R
1
, R
2
, R
3
, R
4
 and R
6
 are as defined for (I), which
is then subjected to an alkylation reaction to yield the

compound (I),

or with a thiourea (METHOD B) of formula

 
wherein R
5
 and R
6
 are as defined for (I), to lead
directly to the compound (I),

and if appropriate the compounds of formula (I) thus
obtained are then optionally separated into their

possible stereoisomers and/or salified to form the
corresponding salts.
Use of the compounds of formula (I) according to
any one of claims 1 to 5 for preparing a medicament

which can be used in the treatment of complaints
requiring modulation of the action of the corticotropic

hormone releasing agent.
Pharmaceutical composition containing as active
principle at least one compound according to any one of

claims 1 to 5 in the form of a base or in the form of a
salt with a pharmaceutically acceptable inorganic or

organic acid, in conjunction with or in admixture with a
pharmaceutically acceptable inert non-toxic excipient.
Pharmaceutical composition according to claim 8, in
the form of dosage units, in which the active principle

is mixed with at least one pharmaceutical excipient.
Composition according to claim 9, wherein each
dosage unit contains 0.5 to 800 mg of active principle.
Composition according to claim 10, wherein each
dosage unit contains 0.5 to 200 mg of active principle.
Pharmaceutical composition containing a compound
according to claims 1 to 5 in conjunction with an

anxiolytic, antidepressant or anorexigenic active
principle.
Compound according to claim 1 wherein R
6
 denotes a
monocyclic heteroaromatic group selected from among: 


azxepine, pyridyl, pyrazinyl, pyridazinyl, pyrimidyl,
triazinyl, furyl and thienyl.
Compound according to claim 1 wherein R
6
 denotes a
bicyclic group selected from among:


1,2,3,4-tatrahydroquinolyl, 1,2,3,4-tetrahydroisoquinolyl,
1,2,3,4-tetrahydrophthalazinyl,

1,2,3,4-tetrahydroquinazolinyl, 1,2,3,4-tetrahydroquinoxalinyl,
1,2,3,4-tetrahydrocinnolinyl,

1,2,3,4-tetrahydrobenzo-triazinyl, chromanyl,
isochromanyl, indolinyl, isoindolin
yl, 2,3-dihydroindazyl,
2,3-dihydrobenzoimidazolyl, 1,2-dihydrobenzotriazolyl,

2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl,
2,3-dihydrobenzoisothiazolyl, 2,3-dihydrobenzothiazolyl,

2,3-dihydrobenzoisoxazolyl; 2,3-dihydrobenzoxazolyl,
1,2-dihydrobenzoxazinyl, 1,2,3,4-tetrahydropteridinyl,

8,9-dihydropurinyl.
</CLAIMS>
</TEXT>
</DOC>
